Publicaciones en colaboración con investigadores/as de University of Dundee (18)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Brain tumour microstructure is associated with post-surgical cognition

    Scientific Reports, Vol. 14, Núm. 1

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2022

  1. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

    ESC Heart Failure, Vol. 9, Núm. 6, pp. 4352-4357

  2. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties

    European Journal of Medicinal Chemistry, Vol. 206

2018

  1. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

    CNS Drugs, Vol. 32, Núm. 5, pp. 455-467

  2. Practitioner review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder

    Journal of Child Psychology and Psychiatry and Allied Disciplines, Vol. 59, Núm. 9, pp. 932-947

2017

  1. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe

    CNS Drugs, Vol. 31, Núm. 7, pp. 625-638

  2. MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia

    Oncotarget, Vol. 8, Núm. 33, pp. 53989-54003

  3. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder

    European Child and Adolescent Psychiatry, Vol. 26, Núm. 11, pp. 1283-1307

2016

  1. Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia

    Frontiers in Oncology, Vol. 6, Núm. APR

2015

  1. Characterization of the autoimmune response against the nerve tissue S100β in patients with type 1 diabetes

    Clinical and Experimental Immunology, Vol. 180, Núm. 2, pp. 207-217

2014

  1. Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/ hyperactivity disorder in a randomized, Controlled trial

    Neuropsychiatric Disease and Treatment, Vol. 10, pp. 2039-2047

2013

  1. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents

    CNS Drugs, Vol. 27, Núm. 9, pp. 743-751

  2. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder

    CNS Drugs, Vol. 27, Núm. 10, pp. 829-840

2005

  1. Mechanism and structure-activity relationships of norspermidine-based peptidic inhibitors of trypanothione reductase

    Bioorganic and Medicinal Chemistry, Vol. 13, Núm. 14, pp. 4513-4526